Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 7.76%
As of Wednesday, July 29, LB Pharmaceuticals Inc’s LBRX share price has surged by 7.76%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Commentary & Analysis
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 9.41%
As of Wednesday, July 22, LB Pharmaceuticals Inc’s LBRX share price has surged by 9.41%, which has investors questioning if this is right time to sell.Michael Rose
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 8.37%
As of Wednesday, June 17, LB Pharmaceuticals Inc’s LBRX share price has surged by 8.37%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Up 5.55%
As of Thursday, June 04, LB Pharmaceuticals Inc’s LBRX share price has surged by 5.55%, which has investors questioning if this is right time to sell.Jenna Brashear
Why LB Pharmaceuticals Inc’s (LBRX) Stock Is Down 5.46%
As of Tuesday, June 02, LB Pharmaceuticals Inc’s LBRX share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,173.2 | $569.9 | 47% |
|
| Shares Out (Mil) | 28.2 | 44.8 | 36% |
|
| Institutional Ownership | 98.9% | 84.6% | 83% |
|
| Float (Mil) | 18.1 | 45.1 | 27% |
|
| Beta | na | 0.67 | na |
|
| Avg Daily Volume (000s) | 398 | 294 | 55% |
|
| Price Change (52-week) |
na | 65.2% | na |
|
| Growth | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $230 | na |
|
| Net Income (TTM) (Mil) | ($39) | ($11) | 18% |
|
| EPS (TTM) | ($2.594) | ($0.600) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($50) | ($6) | 9% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $3 | $7 | 21% |
|
| Enterprise Value (Q1) (Mil) | $564 | $493 | 36% |
|
| Valuation | LBRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.10 | 2.89 | 66% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LBRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | (0.2%) | na |
|
| ROA | (18.2%) | (25.5%) | 21% |
|
| ROE | (27.4%) | (21.4%) | 21% |
|
| Liabilities to Assets | 3.8% | 35.5% | 2% |
|
| F-Score | 1 | 3 | na |
|
LB Pharmaceuticals Inc did not pass any screens on 7/30/2026.
